Ocugen’s OCU410 Cuts GA Lesion Growth 31%, Clears Safety for Phase 3 Launch
Ocugen’s OCU410 gene therapy reduced geographic atrophy lesion growth by 31% versus control at 12 months (p<0.05) in the Phase 2 ArMaDa trial, outperforming current therapies with 15%–22% reductions. No OCU410-related serious adverse events were reported, supporting advancement to a 300-subject Phase 3 trial in Q3 2026.
1. Phase 2 ArMaDa Efficacy Results
In the ArMaDa trial, OCU410 at the medium dose achieved a 31% reduction in geographic atrophy lesion growth versus control at 12 months (p<0.05), alongside a 27% slower rate of ellipsoid zone loss. Fifty-five percent of treated patients experienced at least a 30% lesion size reduction, and a subgroup with baseline lesions 5–17.5 mm² saw a 33% decrease.
2. Safety Profile and Adverse Events
OCU410 displayed a clean safety profile with no related serious adverse events or adverse events of special interest, including no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy. These results align with the favorable safety findings from the earlier Phase 1 study.
3. Trial Design and Phase 3 Plans
The Phase 2 study enrolled 51 patients aged 50+ randomized 1:1:1 to receive a single subretinal injection of OCU410 at 1×10^10 or 3×10^10 vector genomes per eye or control. Ocugen plans to initiate a Phase 3 registrational trial in Q3 2026 with up to 300 subjects and an adaptive design powered over 95%, targeting a BLA filing.
4. Competitive Landscape and Market Potential
Geographic atrophy affects 2–3 million patients in the US and Europe and contributes to vision loss in a global dry AMD population of 266 million. Current treatments require 6–12 annual injections, whereas OCU410’s one-time gene therapy could reduce treatment burden, improve adherence, and address multiple disease pathways.